Thomas P Miller

  • 18820 Citations
  • 57 h-Index
1978 …2021
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Thomas P Miller is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Vincristine Medicine & Life Sciences
Doxorubicin Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1978 2021

CANCER CENTER SUPPORT GRANT

Davis, T. P., Hersh, E. M., Weinstein, R. S., Miesfeld, R., Miller, T. P., Tsaprailis, G., Lynch, R., Chow, H., Nagle, R. B., Watts, G. S., Thomson, C., Roe, D., Stratton, S. P., Alberts, D. S., Hurley, L., Baker, A. F., Livingston, R. B., Dorr, R. T., Cress, A. E., Briehl, M. M., Mash, E. A., Duffy, J., Jones, S., Leibovitz, A., Meyskens, F., Moon, T., Trent, J., Newkirk, D., Von Hoff, D., Mount, D., Doetschman, T., Liebler, D., Marshall, J., McGovern, K., Grogan, T., Kraft, A., Powis, G., Peng, Y., Gerner, E., Aickin, M., Ritenbaugh, C., Taylor, C., Powell, M. B., Bowden, T., Taetle, R., Salmon, S., Ignatenko, N., Bhattacharyya, A. K., Futscher, B. W., Barton, J. K., Montfort, W. "., Roe, D., Garland, L. L., Doetschman, T. C., Kraft, A., Chow, H. & Ellis, N.

National Institutes of Health

9/1/786/30/21

Project: Research project

Neoplasms
Research
Pharmaceutical Services
Research Personnel
Clinical Trials

MEDICAL ONCOLOGY

Alberts, D. S., Hersh, E. M., Miller, T. P., Roe, D., Landowski, T. H., Dorr, R. T., Jones, S., Meyskens, F., Moon, T., Trent, J., Thomas, G., McGee, D., Durie, B. G., Dragovich, T., Gillies, R. J., Taylor, C., Dalton, W., Salmon, S. & Powis, G.

National Institutes of Health

6/1/788/31/13

Project: Research project

Neoplasms
Peptides
Pharmacokinetics
Biometry
Drug Resistance

SOUTHWEST ONCOLOGY GROUP

Miller, T. P. & Cranmer, L.

National Institutes of Health

1/1/7812/31/14

Project: Research project

Neoplasms
Quality Control
Research
Patient Participation
Vulnerable Populations

Research Output 1979 2016

  • 18820 Citations
  • 57 h-Index
  • 164 Article
  • 2 Chapter
  • 1 Letter
15 Citations (Scopus)

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Puvvada, S. D., Li, H., Rimsza, L. M., Bernstein, S. H., Fisher, R. I., LeBlanc, M., Schmelz, M., Glinsmann-Gibson, B., Miller, T. P., Maddox, A. M., Friedberg, J. W., Smith, S. M. & Persky, D. O., Jan 12 2016, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-11 11 p.

Research output: Contribution to journalArticle

Histocompatibility Antigens Class II
B-Cell Lymphoma
Tumor-Infiltrating Lymphocytes
T-Lymphocytes
Tumor Microenvironment
25 Citations (Scopus)

Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J., Sharman, J. P., Schreeder, M. T., Barr, P. M., Foran, J. M., Miller, T. P., Burger, J. A., Kelly, K. R., Mahadevan, D., Ma, S., Li, Y., Pierce, D. W., Barnett, E., Marine, J., Miranda, M., Azaryan, A., Yu, X. & 3 others, Nava-Parada, P., Mei, J. & Kipps, T. J., 2016, In : Haematologica. 101, 7, p. e295-e298

Research output: Contribution to journalLetter

B-Cell Chronic Lymphocytic Leukemia
N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide
Agammaglobulinaemia tyrosine kinase
6 Citations (Scopus)

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Persky, D. O., Miller, T. P., Unger, J. M., Perry, C. S., Puvvada, S. D., Dino Stea, B., Press, O. W., Constine, L. S., Barton, K. P., Friedberg, J. W., LeBlanc, M. & Fisher, R. I., Aug 8 2015, In : Blood. 125, 2, p. 236-241 6 p.

Research output: Contribution to journalArticle

Radiotherapy
B-Cell Lymphoma
Consolidation
Cells
Non-Hodgkin's Lymphoma
22 Citations (Scopus)

Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2

Mahadevan, D., Morales, C., Cooke, L. S., Manziello, A., Mount, D. W., Persky, D. O., Fisher, R. I., Miller, T. P. & Qi, W., Jun 3 2014, In : PLoS One. 9, 6, e95184.

Research output: Contribution to journalArticle

vincristine
Vincristine
lethal genes
mice
Tumors
16 Citations (Scopus)

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

Gustafson, H. L., Yao, S., Goldman, B. H., Lee, K., Perry, C. S., LeBlanc, M. L., Rimsza, L. M., Cerhan, J. R., Habermann, T. M., Link, B. K., Maurer, M. J., Slager, S. L., Persky, D. O., Miller, T. P., Fisher, R. I., Ambrosone, C. B. & Briehl, M. M., 2014, In : American Journal of Hematology. 89, 6, p. 639-645 7 p.

Research output: Contribution to journalArticle

B-Cell Lymphoma
Genetic Polymorphisms
Non-Hodgkin's Lymphoma
Single Nucleotide Polymorphism
Oxidative Stress